Skip to main content
Midas Edge

Disc Medicine Inc

For the period ended Dec 31, 2023. Filed Mar 21, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 21, 2024

IRON$84.64+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Preferred Stock and Stockholders’ Equity (Deficit)

CONSOLIDATED STATEMENTS OF CONVER TIBLE PREFERRED STOCK

AND STOCKHOLDERS’ EQUITY (DEFICIT)

​ · Convertible Preferred Stock · ​ · ​ · ​ · ​ · ​
​ · Series Seed$0.0001 Par Value · Series A$0.0001 Par Value · ​ · Series B$0.0001 Par Value · ​ · Common Stock$0.0001 Par Value · ​ · Additional Paid-In · ​ · Accumulated · ​ · TotalStockholders’
​ · Shares · ​ · Amount · ​ · Shares · ​ · Amount · ​ · Shares · ​ · Amount · ​ · Shares · ​ · Amount · ​ · Capital · Deficit · Deficit
Balance at December 31, 2021​5,000,000​$2,350​41,666,666​$49,762​37,499,999​$89,744​909,418​$—​$1,186​$(65,389)​$(64,203)
Issuance of common stock upon exercise of stock options​—​—​—​—​—​—​53,224​—​219​—​219
Vesting of restricted common stock​—​—​—​—​—​—​8,254​—​—​—​—
Stock-based compensation expense​—​—​—​—​—​—​—​—​2,089​—​2,089
Issuance of common stock for cash in pre-closing financing​—​—​—​—​—​—​2,336,092​—​53,500​—​53,500
Conversion of preferred stock to common stock​(5,000,000)(2,350)(41,666,666)(49,762)(37,499,999)(89,744)​9,224,653​1​141,855​—​141,856
Issuance of common stock to Gemini shareholders in reverse recapitalization​—​—​—​—​—​—​4,389,361​1​91,390​—​91,391
Reverse recapitalization transaction costs​—​—​—​—​—​—​—​—​(7,936)​—​(7,936)
Issuance of common stock to Roche​—​—​—​—​—​—​482,313​—​6,511​—​6,511
Net loss​—​—​—​—​—​—​—​—​—​(46,827)​(46,827)
Balance at December 31, 2022​—​$—​—​$—​—​$—​$17,403,315​$2​$288,814​$(112,216)​$176,600
​ · Convertible Preferred Stock · ​ · ​ · ​ · ​ · ​
​ · Series Seed$0.0001 Par Value · Series A$0.0001 Par Value · ​ · Series B$0.0001 Par Value · ​ · Common Stock$0.0001 Par Value · ​ · Additional Paid-In · ​ · Accumulated · ​ · TotalStockholders’
​ · Shares · ​ · Amount · ​ · Shares · ​ · Amount · ​ · Shares · ​ · Amount · ​ · Shares · ​ · Amount · ​ · Capital · Deficit · Equity
Balance at December 31, 2022​—​$—​—​$—​—​$—​17,403,315​$2​$288,814​$(112,216)​$176,600
Issuance of common stock upon exercise of stock options​—​—​—​—​—​—​254,432​—​2,763​—​2,763
Vesting of restricted common stock​—​—​—​—​—​—​1,916​—​—​—​—
Stock-based compensation expense​—​—​—​—​—​—​—​—​5,530​—​5,530
Sale of common stock in registered direct offering, net of issuance costs of $80​—​—​—​—​—​—​1,488,166​—​34,148​—​34,148
Sale of pre-funded warrants in registered direct offering, net of issuance costs of $66—​—​—​—​—​———28,206—28,206
Sale of common stock in at-the-market offerings, net of issuance costs of $742—​—​—​—​—​—967,264—26,422—26,422
Sale of common stock in follow-on public offering, net of issuance costs of $9,272—​—​—​—​—​—3,015,919—138,508—138,508
Sale of pre-funded warrants in follow-on public offering, net of issuance costs of $627—​—​—​—​—​———9,373—9,373
Issuance of common stock upon exercise of warrants—​—​—​—​—​—1,229,221————
Net loss​—​—​—​—​—​—​—​—​—​(76,429)​(76,429)
Balance at December 31, 2023​—​$—​—​$——​$—24,360,233​$2$533,764​$(188,645)$345,121
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.